Paragon Labs

Paragon Labs Absorbs Apogee Leadership to Accelerate Biologics Pipeline

Paragon Labs has appointed former Apogee Therapeutics executives to its leadership team, including CEO Michael Henderson, to enhance its clinical development capabilities. Simultaneously, Paragon’s spinout Velaris Therapeutics was acquired by Nasdaq-listed Alaunos Therapeutics in a deal backed by a $350 million private placement led by Fairmount. This move follows AbbVie’s $10.9 billion acquisition of Apogee earlier this year, marking a strategic shift for Paragon to leverage operational expertise from its successful spinouts.